fig2

Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population

Figure 2. (A) Probability of progression-free survival according to age: less than 65 years: 17.6 months (95% CI: 10.2-25.0) and 8.2 months (95% CI: 0.1-16.4) in patients older than 65 years. HR = 1.93 (95% CI: 1.2-3.2); P = 0.011; (B) probability of overall survival according to age, 29.0 months (less than 65 years) (95% CI: 11.4-46.5) vs. 19.0 months (older than 65 years) (95% CI: 11.0-26.9) (HR = 1.82; 95% CI: 1.1-3.1); P = 0.022. CI: confidence interval; HR: hazard ratio

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/